retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Dual and Triple Gut Peptide
Description
Chhaya Makhija, MD Do you find yourself struggling to maintain your edge in the boardroom despite your best efforts

.
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
For peptides that target specific areas, like BPC-157 for tendon injuries , some protocols suggest injecting as close to the affected area as practical
However, peak plasma concentrations occur 1 to 3 days after injection, and some users report that GI symptoms, including reflux, are most pronounced during this peak window
